alexa In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Bioequivalence & Bioavailability

Author(s): Bauernfeind A, Petermller C

Abstract Share this page

Abstract The in vitro antibacterial activity of the new quinoline derivative ciprofloxacin (BAY 0 9867) was evaluated in comparison to norfloxacin and nalidixic acid using 495 clinical strains of gram-negative and gram-positive bacteria. The compound was highly active against Enterobacteriaceae, with MICs ranging from 0.008 mg/l to 4 mg/l, whereas the MICs of norfloxacin ranged from 0.03 mg/l to 16 mg/l. All strains of Pseudomonas aeruginosa and Acinetobacter calcoaceticus were inhibited with a concentration of 2 mg/l ciprofloxacin and 32 mg/l norfloxacin. Ciprofloxacin was also active against gram-positive cocci. The MICs for Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus faecalis ranged from 0.008 to 2.0 mg/l. The activity of ciprofloxacin was only slightly influenced by inoculum size, whereas an acid environment caused a noticeable decrease in the activity. Ciprofloxacin would seem to be a promising antibacterial agent for the treatment of urinary tract infection.
This article was published in Eur J Clin Microbiol and referenced in Journal of Bioequivalence & Bioavailability

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version